首页> 外文期刊>Hematological oncology >Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy
【24h】

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy

机译:耐用的缓解患者,患有Myc / Bcl6阳性双击DLBCL的百分之肌擦伤,用Lenalidomide单药治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B‐cell lymphoma and presents as leptomeningeal dissemination in two‐thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6‐positive double‐hit diffuse large B‐cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single‐agent lenalidomide following salvage chemotherapy. Copyright ? 2016 John Wiley & Sons, Ltd.
机译:摘要中枢神经系统的参与是一种罕见的事件,通常在弥漫性大B细胞淋巴瘤的自然病史早期发生,并且在三分之二的病例中呈现为百分症散发。 该事件的预后是令人沮丧的,治疗方案很薄。 虽然中枢神经系统传播的主要经验丰富的危险因素是临床,但最近伴随着Myc / Bcl2蛋白表达的重排以及Myc / Bcl2蛋白表达的增加与这种并发症的风险增加。 在这里,我们提出了第一种情况,介绍了我们的知识,对Myc / Bcl6阳性双击弥漫性大B细胞淋巴瘤复发在裂解物中,通过挽救化疗后达到单孕羊属苯二甲醛胺,达到了良好的耐用缓解。 版权? 2016年John Wiley& SONS,LTD.

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号